We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Axicabtagene Ciloleucel Expanded Access Study (ZUMA-9)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03153462
Recruitment Status : Available
First Posted : May 15, 2017
Last Update Posted : November 29, 2017
Information provided by (Responsible Party):
Kite, A Gilead Company

May 11, 2017
May 15, 2017
November 29, 2017
Axicabtagene Ciloleucel Expanded Access Study
A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma.
Not Provided
Expanded Access
, Treatment IND/Protocol
Biological: Axicabtagene Ciloleucel
Axicabtagene Ciloleucel and A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
Not Provided
Contact: Medical Information 844-454-KITE medinfo@kitepharma.com
United States
Kite, A Gilead Company
Kite, A Gilead Company
Not Provided
Study Director: William Go, MD, PhD Kite, A Gilead Company
Kite, A Gilead Company
August 2017